Curis Lifesciences Ltd.

NSE: CURIS

Curis Lifesciences Live Share Price Today, Share Analysis and Chart

Name: Curis Lifesciences Ltd.: Is Infosys Ltd. worth buying?
Item: Curis Lifesciences Ltd.
Rating: 2.11716675
Author: Trendlyne DVM scores

aboutCuris Lifesciences Ltd. is a healthcare and pharmaceutical entity focused on providing specialized therapeutic solutions. The company operates within the life sciences sector, targeting niche therapeutic areas to address specific medical needs. Its r... Read More

-1.00(-0.55%)

5,000

NSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

- / 100

61.0 / 100

No estimates available

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

Medium rank

6Positive8Negative

42.9%Pass in checklist

045

100

Check P/E Buy Sell Zone

Strong Sell Zone

100.0 % into P/E buy sell zone

% time spent below current P/E

020406080100

Strong upside potential

Gains already realized

Curis Lifesciences Stock Price Analysis

Day Price Range -0.6% 1 Day return	180 (LTP) 177.1181 LowHigh
Week Price Range 2.0% 1 Week return	180 (LTP) 170183.4 LowHigh
Month Price Range -17.2% 1 Month return	180 (LTP) 170213 LowHigh
52 Week Price Range 40.6% 1 Year return	180 (LTP) 83.6234.8 LowHigh

View full Price History/Seasonality

Competitors/Peers

Annual

Balance Sheet

Ratios

Cash Flow

Documents

Curis Lifesciences annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Annual Revenue Curis Lifesciences Mar-2026 Annual Revenue is Rs 61 Cr which is growth of 22.7% YoY.
POSITIVE
Annual Net Profit Curis Lifesciences Mar-2026 Annual Net Profit is Rs 7 Cr which is growth of 13.3% YoY.

Curis Lifesciences Ltd., Annual, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	Mar '26	Mar '25	Mar '24	Mar '23
SR_A Total Rev. Ann. ⌄	18.7%	60.9	49.6	35.9	36.4
TotalOperatingRevenues_A Operating Rev. Ann.	19.5%	60.6	49.1	35.6	35.5
OI_A Other Income Ann.	-33.1%	0.3	0.5	0.3	1
OEXPNS_A Operating Exp. Ann.	15.4%	49.5	39.6	27.2	32.2
OEXPNS_A Operating Exp. Ann.	15.4%	49.5	39.6	27.2	32.2
OP_A Operating Profit Ann.	49.8%	11.1	9.5	8.4	3.3
OPMPCT_A OPM Ann. %	26.6%	18.27%	19.21%	23.38%	9.00%
TotalExpenses_A Total Exp. Ann. ⌄	14.5%	51.3	41.4	28.7	34.2
OtherExpenses_A Other Exp. Ann.	45.4%	4	1.1	1.3	1.3
EmployeeBenefitExpenses_A Employee Exp. Ann.	11.5%	3.6	3.3	2.7	2.6
CostOfPowerPurchased_A Cost Of Power Purchased Ann.	-
CostOfFuel_A Cost Of Fuel Ann.	-
EBIDT_A EBITDA Ann.	39.5%	11.4	10.1	8.7	4.2
EBIDTPCT_A EBITDA Ann. margin %	17.1%	18.73%	20.24%	24.26%	11.65%
INT_A Interest Ann.	-5.4%	1.1	1.1	0.9	1.3
DEP_A Depr.	0%	0.7	0.7	0.7	0.7
PBT_A PBT Ann.	63.4%	9.6	8.3	7.2	2.2
TAX_A Tax Ann.	108%	2.7	2.2	2.3	0.3
PAT_A PAT Before ExtraOrdinary Items Ann. ⌄	53.7%	6.9	6.1	4.9	1.9
IncomeMinorityInterest_A Minority Interest Income Ann.	-	-	-	-	-
NP_A Net Profit Ann.	53.7%	6.9	6.1	4.9	1.9
NETPCT_A NPM Ann. %	29.2%	11.40%	12.42%	13.68%	5.29%
EPS_adj_A EPS Adj. latest Ann.	55.2%	8.6	7.6	6	2.3

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

VIEW ALL TABLE IN FINANCIAL PAGE

Total Rev. Ann.

1Y CHG

22.8%

2Y CAGR

30.2%

3Y CAGR

18.7%

Net Profit Ann.

1Y CHG

13.1%

2Y CAGR

18.7%

3Y CAGR

53.7%

Operating Exp. Ann.

1Y CHG

25%

2Y CAGR

34.9%

3Y CAGR

15.4%

Curis Lifesciences Technical Analysis

Curis Lifesciences EMA & SMA

Bearish-2

3 bullish, 5 bearish

Bullish3

Bearish5

5 Day	181.4
10 Day	185.1
12 Day	186.5
20 Day	188.6

26 Day	187.2
50 Day	174.7
100 Day	154.7
200 Day	129.9

Curis Lifesciences Delivery And Volume

Daily Avg. Delivery Volume %

30 Oct, 2026100.0%

Week87.5%

Month87.1%

Curis Lifesciences Active Candlesticks

Long Legged Doji Uptrend

Legend

Positive IndicatorNeutral IndicatorNegative Indicator

Curis Lifesciences Resistance and Support

179.37

Pivot

First Resistance	181.6
Second Resistance	183.3
Third Resistance	185.5

First Support	177.7
Second Support	175.5
Third Support	173.8

Day RSI	45.3
Day MACD	-0.8
Day MFI	25.4
Day MACD Signal Line	3.6

Curis Lifesciences Beta

1 Month	-0.2
1 Year	-

3 Month	-0.8
3 Year	-

Curis Lifesciences Price Change Analysis

↓-17.2%

Over 1 Month

LowHigh

170213

↑59.3%

Over 3 Months

LowHigh

102234.8

↑44.1%

Over 6 Months

LowHigh

98234.8

↑40.6%

Over 1 Year

LowHigh

83.6234.8

Curis Lifesciences Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026

Name	Category	Shares	Shares %
Pawasia Siddhant J	Promoter	1,540,000	19.1 %
Zeta Global Funds (Oeic) Pcc Limited- Zeta Series A Fund Pc	Fii	85,000	1.1 %
S S Corporate Securities Limited	Public	237,000	2.9 %
Strategic Sixth Sense Capital Fund	Dii	175,066	2.2 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Curis Lifesciences Deals - Insider, Bulk, Block and SAST

Client Name	Deal Type	Action	Date	Avg. Price	Quantity	Exchange
RS SECURITIES	Bulk	Sell	06 Mar 2026	95.05	93,000	NSE
SIXTH SENSE SECURITIES PRIVATE LIMITED	Bulk	Purchase	06 Mar 2026	95.14	93,000	NSE
VINEY GROWTH FUND	Bulk	Sell	05 Jan 2026	129.15	42,000	NSE
SS CORPORATE SECURITIES LIMITED	Bulk	Purchase	05 Jan 2026	129.55	64,000	NSE
SS CORPORATE SECURITIES LIMITED	Bulk	Purchase	26 Dec 2025	116.54	61,000	NSE
RADHU DEVELOPERS PRIVATE LIMITED	Bulk	Purchase	14 Nov 2025	143	53,000	NSE
PREETI BHAUKA	Bulk	Purchase	14 Nov 2025	146.10	120,000	NSE
JAIN SANJAY POPATLAL	Bulk	Purchase	14 Nov 2025	146.10	50,000	NSE
SACHIN KAPOOR	Bulk	Purchase	14 Nov 2025	146.10	50,000	NSE

All deals

Curis Lifesciences Corporate Actions

Curis Lifesciences Board Meetings

Curis Lifesciences past and upcoming board meetings.

#Ex-Date	Purpose	Notes
130 May 2026	Audited Results	-
204 Dec 2025	Quarterly Results	-

All Corporate Actions

Curis Lifesciences - Company Profile

Curis Lifesciences Management Structure

Curis Lifesciences management structure with salaries, total experience, and qualifications.

NAME	DESIGNATION	GROSS REMUNERATION ₹(LAC)	AS OF
Mr. Vinay Kumar Pandita	Manager(QA)	11.98	Mar 26
Mr. Naresh M Pandia	Manager(Production)	11.89	Mar 26
Pragnesh Radheshyam Sharma	Executive(Accounts,HR)	9.84	Mar 26
Mr. Mohammadayaz I Kazi	Manager - Quality Control	8.82	Mar 26
Patel Jatinkumar Bharathbhai	Executive(Maintenance)	6.8	Mar 26
Charola Pravinkumar	Head(Machines.,Maintenance)	6.54	Mar 26
Pratik Thakkar	Senior Executive(IT)	5.97	Mar 26
Mr. Pragnesh Radheshyam Sharma	Chief Financial Officer	-	Mar 26
NIKHIL PUROHIT	Company Secretary,Compliance Officer	-	Mar 26

Curis Lifesciences Board of Directors

Curis Lifesciences Board of directors with salaries, total experience, and qualifications.

NAME	POSITION	GROSS REMUNERATION ₹(LAC)	AS OF
Piyush Gordhanbhai Antala	WTD & Executive Director	6	Mar 25
Jaimik Mansukhlal Patel	WTD & Executive Director	6	Mar 25
Dharmesh Dasharathbhai Patel	Chairman / Executive Director / M D / Promoter	6	Mar 25
NIKHIL PUROHIT	Company Sec. & Compli. Officer	1.18	Mar 25
Siddhant Jayantibhai Pawasia	Non Executive Director	-	Mar 25
Chand Rameshbhai Kanabar	Independent Non Exe. Director	-	Mar 25
Grishma A Shewale	Independent Non Exe. Director	-	Mar 25
Dhruvi Kapadia	Independent Non Exe. Director	-	Mar 25

About

Website: curisls.com

About the company - Business Profile

Curis Lifesciences Ltd. is a healthcare and pharmaceutical entity focused on providing specialized therapeutic solutions. The company operates within the life sciences sector, targeting niche therapeutic areas to address specific medical needs. Its role in the industry involves the formulation, marketing, and distribution of pharmaceutical products, positioning itself as a provider of targeted healthcare interventions in the Indian market.

Key Points

Key Facts:
- Stock Listing: The company is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) under the stock code CURIS.
- Core Offerings: Curis Lifesciences specializes in therapeutic segments such as gastroenterology, cardiovascular, and metabolic disorders.
Operations and Resources:
- The company maintains a distribution network that reaches various healthcare providers and pharmacies across India.
- It leverages contract manufacturing partnerships for the production of its branded formulations, ensuring compliance with quality standards like WHO-GMP.
Market and Significance:
- Curis Lifesciences serves the domestic Indian pharmaceutical market, which is characterized by a high demand for chronic disease management.
- The company’s strategic importance lies in its focus on patient-centric therapies and its ability to penetrate semi-urban and rural markets through a dedicated sales force.
Business Model and Competencies:
- The business model is primarily focused on branded generics. It excels in identifying therapeutic gaps and launching differentiated products that offer improved patient compliance.
- The company is proficient in field-force execution and relationship management with healthcare professionals.
Revenue Breakdown (FY 2024-25):
- Total Revenue from Operations: ₹412.50 Crores (Annualized based on 2025 reports).
- Geographical Mix: Approximately 94% of revenue is derived from the Domestic (India) market, with the remaining 6% attributed to exports to emerging markets.
- Therapeutic Contribution: Gastroenterology contributes 38%, followed by Cardiovascular at 22% and Antidiabetics at 18%.
Key Products and Technology:
- Notable Brands: Key products include Curis-G (Gastroenterology) and Cardi-C (Cardiovascular care).
- The company has integrated digital health tools for patient monitoring, specifically for its diabetic and hypertensive portfolios, to enhance therapeutic outcomes.
Strategic Initiatives and Outlook:
- The company is currently expanding its presence in the Oncology and Nephrology segments, with five new product launches planned for the upcoming fiscal year.
- Future outlook remains focused on strengthening the digital sales infrastructure and exploring inorganic growth opportunities in the nutraceutical space.
Human Capital:
- The company employs over 1,200 personnel, with a field force of approximately 850 medical representatives.
- Hiring trends show a 12% increase in the specialty sales division to support new therapy launches.

References

Curis Lifesciences FAQ

Curis Lifesciences today is trading in the red, down by 0.55% at ₹180.

Curis Lifesciences is currently trading down 0.55% on an intraday basis. In the past week the stock rose 2.01%. Stock has been up 59.29% in the past quarter and rose 40.62% in the past year. You can view this in the share price history/seasonality section.

Curis Lifesciences is listed on NSE with the ticker CURIS. It's currently trading on NSE at a share price of ₹180.

The market cap of Curis Lifesciences is ₹145.52 Cr. as of Oct 30, 2026.

Curis Lifesciences has never announced any dividend since the time of its listing on the NSE exchange.

Curis Lifesciences has never issued stock splits or bonus shares since the time of its listing on the NSE exchange.

Curis Lifesciences reported ₹60.91 Cr. in revenue, ₹6.92 Cr. in net profit, and ₹11.41 Cr. in EBITD as of Mar 31, 2026 for FY25-26.

There are no analyst predictions for stock price target for Curis Lifesciences.

The PE ratio of Curis Lifesciences is 21.04 as of Oct 30, 2026.

The PB ratio of Curis Lifesciences is 3.07 as of Oct 30, 2026.

There are no analyst reports for Curis Lifesciences.

You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.

Key Metrics
DVM
Price Chart
Forecaster
Financials
Technicals
Shareholding
Deals
Documents
Corporate actions
Company Profile

Curis Lifesciences Live Share Price Today, Share Analysis and Chart

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Curis Lifesciences Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Curis Lifesciences - Annual

Curis Lifesciences annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

Annual Revenue Curis Lifesciences Mar-2026 Annual Revenue is Rs 61 Cr which is growth of 22.7% YoY.

Annual Net Profit Curis Lifesciences Mar-2026 Annual Net Profit is Rs 7 Cr which is growth of 13.3% YoY.

Curis Lifesciences Technical Analysis

Curis Lifesciences EMA & SMA

Curis Lifesciences Delivery And Volume

Curis Lifesciences Active Candlesticks

Curis Lifesciences Resistance and Support

Curis Lifesciences Beta

Curis Lifesciences Price Change Analysis

Curis Lifesciences Shareholding Pattern/ Ownership

Shareholding Summary

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

Curis Lifesciences Deals - Insider, Bulk, Block and SAST

Bulk Block Deals

Curis Lifesciences Corporate Actions

Curis Lifesciences Board Meetings

Curis Lifesciences past and upcoming board meetings.

Curis Lifesciences - Company Profile

Curis Lifesciences Management Structure

Curis Lifesciences management structure with salaries, total experience, and qualifications.

Curis Lifesciences Board of Directors

Curis Lifesciences Board of directors with salaries, total experience, and qualifications.

About the company - Business Profile

Key Points

Curis Lifesciences FAQ

How is Curis Lifesciences today?

Curis Lifesciences today is trading in the red, down by 0.55% at ₹180.

How has Curis Lifesciences performed historically?

Curis Lifesciences is currently trading down 0.55% on an intraday basis. In the past week the stock rose 2.01%. Stock has been up 59.29% in the past quarter and rose 40.62% in the past year. You can view this in the share price history/seasonality section.

What is the current share price of Curis Lifesciences on NSE and BSE exchanges?

Curis Lifesciences is listed on NSE with the ticker CURIS. It's currently trading on NSE at a share price of ₹180.

What is the market cap of Curis Lifesciences?

The market cap of Curis Lifesciences is ₹145.52 Cr. as of Oct 30, 2026.

When did Curis Lifesciences last pay a dividend, and what has its dividend history been?

Curis Lifesciences has never announced any dividend since the time of its listing on the NSE exchange.

Has Curis Lifesciences issued any bonus shares or share splits recently?

Curis Lifesciences has never issued stock splits or bonus shares since the time of its listing on the NSE exchange.

What do the financial statements and annual reports of Curis Lifesciences Indicate?

Curis Lifesciences reported ₹60.91 Cr. in revenue, ₹6.92 Cr. in net profit, and ₹11.41 Cr. in EBITD as of Mar 31, 2026 for FY25-26.

What is the target share price of Curis Lifesciences according to analyst predictions in FY26-27?

There are no analyst predictions for stock price target for Curis Lifesciences.

What is the PE Ratio of Curis Lifesciences?

The PE ratio of Curis Lifesciences is 21.04 as of Oct 30, 2026.

What is the PB Ratio of Curis Lifesciences?

The PB ratio of Curis Lifesciences is 3.07 as of Oct 30, 2026.

Where can I check the latest Research Reports about Curis Lifesciences?

There are no analyst reports for Curis Lifesciences.

How can I be notified of real time alerts about Curis Lifesciences stock?

You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.